Metagenomi, Inc. (MGX) - Uzoq muddatli qarzning kapitalga nisbati
Metagenomi, Inc. (MGX) samaradorligi sog'liqni saqlash gigantlari bilan strategik ittifoqlarga va shaffof risk-menejmentga asoslangan. Uzoq muddatli kreditlarning kapitalga nisbati moliyaviy barqarorlikni ifodalaydi, bunda 0.27 belgisi ushbu metrikani aks ettiradi. Kompaniya ekologik emissiyalarni filtrlash standartlariga qat'iy rioya qiladi, uning shaxsiy CRISPR platformasi esa kuchli raqobatbardoshlik ustunligini yaratib, genom tahrirlash sektorida texnologik ustunlikni ta'minlaydi.
%20Uzoq%20muddatli%20qarzning%20o'z%20kapitaliga%20nisbati&width=1200&height=400&colorIndex=0&v=mvx9zauv.4e-7b561vk&start=20220704&end=20261101&filename=GURU_Markets_-_MGX_-_Metagenomi-Inc._-_Long-Term-Debt-to-Equity "metagenomi.co (MGX): Uzoq muddatli qarzning o'z kapitaliga nisbati 21.02.2024dan 31.10.2026gacha | 👁️GURU.Markets👁️")
Metagenomi, Inc. (MGX) boʻyicha keng qamrovli koʻrsatkichlar kesimi va tahlil
- joriy narx va aksiyalarning prognoz qilingan qiymati:
- bozor kapitallashuvi ko'rsatkichlari:
- kompaniyaning balans qiymati tafsilotlari:
- kompaniyaning majburiyatlari va likvidligi ma'lumotlari:
Jamlagan qarzning kapitalga nisbati Metagenomi, Inc.|MGX - Uzoq muddatli qarzning kapitalga nisbati|Qisqa muddatli qarzning kapitalga nisbati metagenomi.co|MGX - Kompaniyaning jamlangan qarzlari|Qarzning sof aktivlarga nisbati Metagenomi, Inc.|MGX - Kompaniyaning uzoq muddatli qarzlari|Qisqa muddatli qarz Metagenomi|Shoshilinch likvidlik koeffitsiyenti metagenomi.co
- kompaniyaning daromadliligi va baholash multiplikatorlari ko'rsatkichlari:
Kompaniyaning jamlanma tahlili:MGX - Metagenomi Inc.
Ushbu koeffitsient bir yildan ortiq muddatli majburiyatlarni kapital miqdori bilan solishtiradi. Mazkur metrika kompaniyaning qarz moliyalashtirishga bog'liqlik darajasini va defoltga nisbatan barqarorligini belgilaydi. GURU.Markets platformasida uzoq muddatli qarzning kapitalga nisbati tendentsiyasini tahlil qilish orqali investor moliyaviy ehtiyotkorlik va kengayish o'rtasidagi muvozanatni baholaydi. Metagenomi, Inc. (MGX) uchun uzoq muddatli patent sikllarini yaratishda past qarz yuklamasi hal qiluvchi ahamiyatga ega. Bu kreditorlar bosimisiz genom tahrirlash tizimini ishlab chiqishning avtonomligini ta'minlaydi.
Muhim raqobatchilar
Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi TEM (Tempus)|Uzoq muddatli qarzning kapitalga nisbati QGEN|Uzoq muddatli qarzning kapitalga nisbati Isis Pharmaceuticals (IONS)|Uzoq muddatli qarzning o'z kapitaliga nisbati Repligen Corporation RGEN|RNA - Uzoq muddatli qarzning o'z kapitaliga nisbati|CRISPR Therapeutics - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati GeneDx Holdings|RARE (Ultragenyx Pharma) - Uzoq muddatli qarzning o'z kapitaliga nisbati|BEAM: Uzoq muddatli kreditlarning kapitalga nisbati|SRPT (Sarepta Therapeutics, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning kapitalga nisbati twistbioscience.com|Uzoq muddatli qarzning kapitalga nisbati TXG|Intellia Therapeutics Inc (NTLA) - Uzoq muddatli qarzdorlikning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga nisbati STOK (Stoke)|BioLife (BLFS) - Uzoq muddatli majburiyatlarning kapitalga nisbati|WVE - Uzoq muddatli qarzning o'z kapitaliga nisbati|MAZE (mazetx.com) - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Sionna Therapeutics (SION) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Prime Medicine Inc (PRME)|Uzoq muddatli qarzning o'z kapitaliga nisbati Taysha|Uzoq muddatli qarzning o'z kapitaliga nisbati uniQure Pharma (QURE)|Uzoq muddatli qarzning kapitalga nisbati MGTX|Uzoq muddatli qarzdorlikning kapitalga nisbati regenxbio.com|Solid Biosciences - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga koeffitsiyenti OCGN|Pacific Biosciences of California - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzdorlikning kapitalga nisbati Benitec Corp BNTC|Design Therapeutics (DSGN) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi RCKT|FDMT (4D Molecular Therapeutics, Inc.) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning o'z kapitaliga nisbati Lexeo (LXEO)|Uzoq muddatli qarzning o'z kapitaliga nisbati KRRO (Korro Bio, Inc.)|Uzoq muddatli qarzdorlikning kapitalga nisbati Editas Corp|Uzoq muddatli qarzning o'z kapitaliga nisbati Silence Therapeutics SLN|PRQR - Uzoq muddatli qarzning o'z kapitaliga nisbati|Codexis Bio - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzdorlikning o'z kapitaliga nisbati Sangamo Therapeutics Inc. (SGMO)|NAUT (nautilus.bio) - Uzoq muddatli qarzning o'z kapitaliga nisbati|Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi DTIL|GBIO (Generation Bio Co) - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi BOLD (boundlessbio.com)|Uzoq muddatli qarzning o'z kapitaliga nisbati Exicure, Inc. (XCUR)|imunon.com - Uzoq muddatli qarzning kapitalga nisbati ko'rsatkichi|Uzoq muddatli qarzning kapitalga nisbati PHIO (Phio Pharmaceuticals Corp.)|Uzoq muddatli qarzning kapitalga nisbati Mustang Bio Inc MBIO|RNAZ - Uzoq muddatli qarzning o'z kapitaliga nisbati|Bionano Genomics, Inc. (BNGO) - Uzoq muddatli qarzning o'z kapitaliga nisbati|APDN: Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati bluebird bio Inc. (BLUE)|Uzoq muddatli qarzning o'z kapitaliga nisbati IPA|OMGA (Omega Therapeutics Corp) - Uzoq muddatli kreditlarning kapitalga nisbati|Uzoq muddatli qarzning kapitalga nisbati OMIC|Uzoq muddatli qarzning kapitalga nisbati regulusrx.com (RGLS)|Uzoq muddatli qarzning kapitalga nisbati SYRS (Syros Pharmaceuticals, Inc.)|Uzoq muddatli qarzdorlikning o'z kapitaliga nisbati Telesis Bio Inc.|TRACON - Uzoq muddatli qarzning kapitalga nisbati|Uzoq muddatli majburiyatlarning kapitalga nisbati Unity Biotechnology, Inc